Pharmacokinetics of ara-C and ara-U in plasma and CSF after high-dose administration of cytosine arabinoside.

Abstract

Cytosine arabinoside (ara-C) and uracil arabinoside (ara-U) levels were measured in the plasma, cerebrospinal fluid (CSF), and urine of 10 patients exhibiting primary central nervous system lymphoma who received 31 infusions of high-dose ara-C (3 g/m2) as part of their treatment regimen. Peak plasma and CSF ara-C levels were 10.8 and 1.5 micrograms/ml, respectively. Ara-C was cleared more rapidly from plasma than from CSF. Ara-U appeared rapidly in both plasma and CSF, reaching a peak that was 10 times higher than the corresponding ara-C concentration (104 and 11.2 micrograms/ml, respectively). Only 4%-6% of the dose was excreted unchanged in the urine, but 63%-73% of it appeared as ara-U within the first 24 h. The presence of leptomeningeal lymphoma did not affect the CSF level of ara-C or ara-U.

• Authors: L M DeAngelis, W Kreis, K Chan, E Dantis, S Akerman
• Journal: Cancer chemotherapy and pharmacology (Cancer Chemother Pharmacol) Vol. 29 Issue 3 Pg. 173-7 ( 1992) ISSN: 0344-5704 [Print] Germany
• PMID: 1733548 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Cytarabine
• Arabinofuranosyluracil

Topics

• Arabinofuranosyluracil (administration & dosage, pharmacokinetics)
• Central Nervous System Neoplasms (drug therapy, radiotherapy)
• Combined Modality Therapy
• Cytarabine (administration & dosage, pharmacokinetics)
• Female
• Half-Life
• Humans
• Lymphoma (drug therapy, radiotherapy)
• Male
• Metabolic Clearance Rate
• Middle Aged